Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease

American Journal of Cardiology

Volumn 95, Issue 2, 2005, Pages 249-253

  Dorval, Jean Francois ^a   Anderson, Todd ^b   Buithieu, Jean ^a   Chan, Sammy ^c   Hutchison, Stuart ^d   Huynh, Thao ^a   Jobin, Jean ^e   Lonn, Eva ^f   Poirier, Paul ^e   Title, Lawrence ^g   Walling, Ann ^h   Tran, Thang ⁱ   Boudreau, Ghyslain ⁱ   Charbonneau, Francois ^j   Genest, Jacques ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b O ^*  (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h MCGILL UNIVERSITY   (Canada)

ⁱ PFIZER INC   (United States)

^j FOOTHILLS HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; DRUG USE; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTICENTER STUDY; PATIENT; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 19944427900     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.09.012     Document Type: Article

References (20)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
2. J. Genest, J. Frohlich, G. Fodor, R. McPherson Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update Can Med Assoc J 169 2003 921 924
3. G. De Backer, E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cifkova, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia the European Society of Cardiology Committee for Practice Guidelines European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts) Eur J Cardiovasc Prev Rehabil 10(suppl) 2003 S1 S10
4. J. Genest, T.R. Pedersen Prevention of cardiovascular ischemic events: high-risk and secondary prevention Circulation 107 2003 2059 2065
5. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr, D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr, E.J. Roccella The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
6. B.R. Hemmelgarn, K.B. Zarnke, N.R. Campbell, R.D. Feldman, D.W. McKay, F.A. McAlister, N. Khan, E.L. Schiffrin, M.G. Myers, P. Bolli The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: part I-blood pressure measurement, diagnosis and assessment of risk Can J Cardiol 20 2004 31 40
7. European Society of Hypertension-European Society of Cardiology Guideline Committee 2003 European Society of Hypertension--European Society of Cardiology guidelines for the management of arterial hypertension J Hypertens 21 2003 1011 1053
8. K. Wolf-Maier, R.S. Cooper, H. Kramer, J.R. Banegas, S. Giampaoli, M.R. Joffres, N. Poulter, P. Primatests, B. Stegmayr, M. Thamm Hypertension treatment and control in five European Countries, Canada and the Unites States Hypertension 43 2004 10 17
9. R.M. Touyz, N. Campbell, A. Logan, N. Gledhill, R. Petrella, R. Padwal Canadian Hypertension Education Program The 2004 Canadian recommendations for the management of hypertension: part III--lifestyle modifications to prevent and control hypertension Can J Cardiol 20 2004 55 59
10. EUROASPIRE I and II Group European Action on Secondary Prevention by Intervention to Reduce Events Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events Lancet 357 2001 972 973
11. D. Vanuzzo, L. Pilotto, G.B. Ambrosio, K. Pyorala, S. Lehto, D. De Bacquer, G. De Backer, D. Wood European Action on Secondary Prevention through Intervention to Reduce Events Atherosclerosis 153 2000 505 517
12. T.A. Pearson, I. Laurora, H. Chu, S. Kafonek The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 2000 459 467
13. S.M. Grundy Coordinating Committee of the National Cholesterol Education Program Implication of recent clinical trials for the National Cholesterol Education Program adult Treatment Panel III Guidelines Circulation 110 2004 227 239
14. Genest J, Libby P, Gotto AM. Lipoprotein disorders and cardiovascular risk. In: Braunwald E, Libby P, Zipes D, eds. Braunwald's Heart Disease. Philadelphia: WB Saunders, 2004;1013-1033.
15. H.C. Bucher, L.E. Griffith, G.H. Guyatt Systematic review on the risk and benefit of different cholesterol-lowering interventions Arterioscler Thromb Vasc Biol 19 1999 187 195
16. N. Freemantle, J. Cleland, P. Young, J. Mason, J. Harrison Beta blockade after myocardial infarction: systematic review and meta regression analysis BMJ 26318 1999 1730 1737
17. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
18. K.M. Fox Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
19. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Kober, A.P. Maggioni, S.D. Solomon, K. Swedberg, F. Van de Werf, H. White Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
20. S.E. Nissen, E.M. Tuzcu, P. Schoenhagen, B.G. Brown, P. Ganz, R.A. Vogel, T. Crowe, G. Howard, C.J. Cooper, B. Brodie, C.L. Grines, A.N. DeMaria the REVERSAL Investigators Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080